Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.39 |
| ▸ | TNF | P01375 | 4/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.39 |
| ▸ | CD38 | P28907 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647429 | 0.84 | NOD1 (0.45) | PLAUNOD1TNFNOD2LMNA | |
| SCHEMBL6644942 | 0.84 | PLAU (0.40) | PLAUNOD1CD38ITGB3ITGA2B | |
| SCHEMBL6645706 | 0.81 | NOD1 (0.38) | PLAUNOD1TNFNOD2ITGB3 | |
| SCHEMBL6647009 | 0.80 | PLAU (0.44) | PLAUNOD1ITGB3ITGA2BLMNA | |
| SCHEMBL6649475 | 0.79 | TMPRSS2 (0.47) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6644871 | 0.73 | F2 (0.50) | PLAUMEN1KMT2A | |
| SCHEMBL690395 | 0.73 | MTTP (0.51) | LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL6502283 | 0.70 | NOD1 (0.40) | PLAUNOD1TNFNOD2ITGB3 | |
| SCHEMBL6643806 | 0.70 | PDE7A (0.43) | PLAUSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL6645222 | 0.70 | MAPT (0.44) | LMNASMN1; SMN2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | PLAU 4416/4885NOD1 850/4885TNF 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.